Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055783 | PMC |
| http://dx.doi.org/10.1167/iovs.10-6275 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Addition of Bevacizumab to Chemotherapy and Its Impact on Clinical Efficacy in Cervical Cancer: A Systematic Review and Meta-Analysis.
Pharmacy (Basel)
December 2024
Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, George Town 11800, Penang, Malaysia.
: Cervical cancer is the third leading cause of cancer-related mortality in females. One of the most successful therapeutic modalities to date is suppressing vascular endothelial growth factor (VEGF)-mediated angiogenesis. Bevacizumab is a monoclonal antibody that targets VEGF-A.
View Article and Find Full Text PDFSuppressing, stimulating and/or inhibiting: The evolving management of HCC patient after liver transplantation.
Crit Rev Oncol Hematol
December 2024
Department of Oncology and Hematology, Oncology Unit, University Hospital of Modena and Reggio Emilia, University of Modena and Reggio Emilia, Modena 41124, Italy. Electronic address:
Liver transplantation (LT) is a curative strategy for hepatocellular carcinoma (HCC), but the risk of HCC recurrence remains a challenging problem. In patients with HCC recurrence after LT (HCC-R_LT), the locoregional and surgical approaches are complex, and the guidelines do not report evidence-based strategies for the management of immunosuppression. In recent years, immunotherapy has become an effective option for patients with advanced HCC in pre-transplant settings.
View Article and Find Full Text PDFFirst-line immune checkpoint inhibitor (ICI) combinations show responses in subsets of hepatocellular carcinoma (HCC) patients. Nearly half of HCCs are Wnt-active with mutations in (encoding for β-catenin), , or , and demonstrate limited benefit to ICI due to an immune excluded tumor microenvironment. We show significant tumor responses in multiple β-catenin-mutated immunocompetent HCC models to a novel siRNA encapsulated in lipid nanoparticle targeting (LNP-CTNNB1).
View Article and Find Full Text PDFSerum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol
December 2024
Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, 734-8551, Japan.
Background: This study aims to identify biomarkers for treatment response of atezolizumab plus bevacizumab (Atezo+Bev) in patients with hepatocellular carcinoma (HCC).
Methods: 96 patients who received Atezo+Bev or lenvatinib as a first-line systemic therapy were enrolled as the training group after propensity score matching (PSM), and 42 patients treated with Atezo+Bev were enrolled as the validation group. 17 serum cytokines were measured by Luminex multiplex assay at the start of treatment.
Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms.
Clin Respir J
October 2024
Department of Respiratory and Critical Care Medicine, Chongqing University Jiangjin Hospital, Chongqing, China.
Article Synopsis
- Osimertinib is an FDA-approved treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations, but almost half of patients experience resistance to it, with unknown mechanisms and controversial treatment options after progression.
- This retrospective study analyzed 121 advanced NSCLC patients who progressed after osimertinib, comparing efficacy and safety of three treatment regimens: immunotherapy plus chemotherapy, chemotherapy alone, and osimertinib plus bevacizumab.
- Results showed that the immunotherapy plus chemotherapy group had a significantly higher objective response rate (55.56% vs. 14.81% and 0%) and longer progression-free survival (8.2 months vs. 4.0 months and
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!